Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation
Crossref DOI link: https://doi.org/10.1038/bmt.2017.65
Published Online: 2017-04-03
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yamamoto, S
Matsuno, R
Sugishita, Y
Kaneko, R
Okamoto, N
Koganesawa, M
Fujita, S
Akiyama, K
Toyama, D
Isoyama, K
Text and Data Mining valid from 2017-04-03
Version of Record valid from 2017-04-03
Article History
First Online: 3 April 2017
Competing interests
: The authors declare no conflict of interest.